News Information
Focusing on cutting-edge technology and conveying industry voices
On November 13, 2024, at 12:00 p.m., Invizyne Technologies, Inc. made its debut on the Nasdaq, raising $15 million through an initial public offering. Invizyne is a leading designer of cell-free synthetic biomanufacturing systems, which are used to produce high-value chemicals such as active pharmaceutical ingredients (APIs), biofuels, food flavorings, fragrances, and cosmetics. This successful IPO could herald a new era in biomanufacturing, enabling enzymatic pathways to operate beyond the constraints of living cells.
2024/11/15
On August 21, at the gracious invitation of the Hong Kong Darts Innovation Center, a three‑person delegation from Perotin Bio traveled to Hong Kong to attend the “ATLATL x HKSTP Early‑Stage Healthcare Project Sharing and Exchange Meeting.” As an innovative company specializing in cell‑free protein synthesis technology, Perotin Bio has successfully completed small‑scale validation of its proprietary, cutting‑edge cell‑free protein synthesis approach across a range of proteins and peptides, delivering significant advantages in both time and cost compared with conventional biosynthetic methods. This event provided the company with a valuable platform for in‑depth dialogue with industry peers and collaborative exploration of pioneering healthcare initiatives.
2024/09/02
From biomanufacturing to drug discovery, CFPS is spearheading a wave of innovation.
The high efficiency, flexibility, and low cost of cell-free systems have increasingly elevated their importance in biological systems engineering. With this platform, researchers can gain deep insights into and exert precise control over biomolecular processes, monitor reactions in real time, and fine-tune reaction parameters, enabling highly efficient biosensing and biomanufacturing. Moreover, when integrated with machine learning, cell-free systems significantly enhance protein yield and accelerate prototype design. Looking ahead, cell-free expression systems hold great promise for applications across industries such as pharmaceuticals and biomanufacturing, positioning them as a pivotal frontier in the advancement of biotechnology.
2024/05/24
Cell-free protein expression technology and brazzein together usher in a new “sweet” era of health!
With advances in cell-free protein synthesis (CFPS) technology, its application in the food industry has steadily expanded. This has made large-scale production of brazzein possible, broadening its use across sectors such as food and beverages. Perotin Bio has long been committed to the research, development, and commercialization of cell-free protein expression technologies, with deep expertise in this field. Leveraging its independently developed, uniquely distinctive cell-free protein expression platform, the company has successfully established a manufacturing process for brazzein, enabling its large-scale production.
2024/05/13
2024’s New Favorite in Synthetic Biology Investment: Cell-Free Protein Synthesis
In March this year, SynBioBeta released its “2024 Synthetic Biology Annual Investment Report,” which summarizes and analyzes global investment and financing trends in synthetic biology for 2023, while providing detailed insights into upstream and downstream investment dynamics across multiple sectors. Additionally, the report ranks the top ten global investment projects in various segments of the synthetic biology field for 2023. For investors and entrepreneurs interested in synthetic biology, this report offers invaluable market insights and industry updates, highlighting a trend that cannot be overlooked: cell-free protein synthesis technology is emerging as a new hot spot for capital investment. Several companies specializing in this technology have repeatedly appeared on leading rankings, attracting substantial funding. Against the backdrop of growing global economic uncertainty, synthetic biology—as an emerging field—continues to demonstrate its unique value and potential. In particular, cell-free protein synthesis, with its efficiency, environmental friendliness, sustainability, and cost-effectiveness, is rapidly becoming a favorite within the biotechnology sector. The report highlights three companies—Tierra Biosciences, LenioBio, and Sutro Biopharma—as leaders in cell-free protein synthesis technology, each appearing multiple times on top‑ten lists across different evaluation criteria. These companies’ successful fundraising rounds not only underscore the market potential and investment appeal of cell-free protein synthesis but also provide domestic investors with fresh perspectives and opportunities for engagement. Tierra Biosciences
2024/04/19
Cell-free protein synthesis (CFPS) systems, with their distinctive “open” architecture, are emerging as powerful tools for elucidating the mechanisms of transcription and translation within cells. In recent years, CFPS platforms have become indispensable instruments in bioengineering and biotechnology, capable not only of mimicking transcription and translation but also serving as a rapid prototyping platform for biotechnological applications—particularly well suited for computer-aided design and preliminary testing of in vitro production systems.
2024/04/01
A New Approach to Optimizing the Synthesis Process of Azoreductase: Cell-Free Protein Expression
This study aims to develop a CFPS‑based screening platform that integrates in vitro activity assays on porous microtiter plates, enabling the parallel screening of multiple candidate genes. This approach allows for the rapid and straightforward identification of gene candidates suitable for biotechnological applications. Using CFPS technology, the researchers synthesized several candidate azoreductases that had not previously undergone biochemical characterization and evaluated their ability to cleave azo bonds in in vitro assays. The study demonstrates for the first time that azoreductases can be expressed in an active form within an E. coli–based CFPS system. In the future, this systematic screening strategy will facilitate the efficient identification of additional functionally important proteases within a short timeframe.
2024/03/14
Contact Information
Service Hotline: +86-512-67900128
Customer Service: order@sz-pld.tech
Business Cooperation: bd@sz-pld.tech
Address: Room 302, Building 1, Weili Medical Science and Technology Park, No. 69 Jiepu Road, Suzhou Industrial Park
